Ketoprofen is under clinical development by Achelios Therapeutics and currently in Phase II for Arthralgia (Joint Pain). According to GlobalData, Phase II drugs for Arthralgia (Joint Pain) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ketoprofen LoA Report. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ketoprofen overview

Ketoprofen (ELSM-11,Topofen) is under development for the treatment of a menstrual migraine, temporomandibular joint disorders (joint pain). The drug candidate is applied topically as formulated in the gel and liquid spray forms. The drug candidate acts by targeting prostaglandin G/H synthase (cyclooxygenase or COX). 
It was under development for the treatment of osteoarthritis and sprains and strains.

Achelios Therapeutics overview

Achelios Therapeutics (Achelios) is a pharmaceutical company that develops new therapeutic entities (NTE) for the treatment of pain and inflammation by topically delivered medications. The company pipeline products include Topofen, which is formulated using topical Achetogel topical delivery platform for the indication of temporomandibular joint disease (TMJD) and menstrual migraine. Its other pipelines include Ditogel and Ditogel and Topregel for the indication of chronic pain and temporary relief of joint and muscle pain. The company also developing applications for topical NSAID (nonsteroidal anti-inflammatory drug) therapy such as gout, foot pain, neuropathic pain and postherpetic neuralgia. Achelios is headquartered in Durham, North Carolina, the US.

For a complete picture of Ketoprofen’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.